Latest News

Sage turns down Biogen's $469 million takeover deal, states deal undervalues company

Sage turns down Biogen's $469 million takeover deal, states deal undervalues company

Sage Rehabs said on Monday that its board has actually unanimously rejected Biogen's. $ 469 million deal, specifying it considerably undervalues the. business and does not serve shareholders' best interests.

Biogen, which currently holds a 10.2% stake in Sage,. proposed to obtain all impressive Sage shares it does not. already own for $7.22 per share.

Shares of Sage were up 5.3% at $7.48 in early trading.

Sage revealed it has initiated a process to explore. strategic alternatives however has not set a timeline for the. evaluation.

The business mentioned it will not supply updates unless. essential.

Sage shares plunged 74.9% in 2015 after ceasing. the development of its experimental drug dalzanemdor due to. trial failures.

In October, the Massachusetts-based business

revealed

the departure of Chief Financial Officer Kimi Iguchi and. laid off over 165 staff members as part of a reorganization to focus. on the launch of its postpartum anxiety tablet, Zurzuvae.

The U.S. Food and Drug Administration authorized Zurzuvae,. co-developed with Biogen, for postpartum anxiety in 2023.

Sage stopped development of another neurological drug. with Biogen in July.

(source: Reuters)